Ranking Shkreli science on the Q3 Biotech Scorecard

We’ll be keeping a close eye on a select few biotechs, and their stock prices, this quarter — and tracking it, as always, with our handy-dandy Biotech Scorecard. 

Among the highlights: Sangamo Therapeutics will be presenting updated clinical data for its experimental hemophilia A gene therapy. The readout, if positive, could help it gain ground in a competition against competitors Biomarin and Spark Therapeutics. Aimmune Therapeutics, meantime, has a big milestone forthcoming: Its peanut allergy treatment will be up for review by an FDA advisory committee in September.

We’re also awaiting top-line Phase 3 data from Retrophin — with a drug, fosmetpantotenate, that was co-invented by Martin Shkreli.

Read more about our 12 stock-moving events to watch.